Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile ...
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
HAMPTON, N.J., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Celldex ( NASDAQ: CLDX ) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L ...
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer - Celldex Therapeutics ( NASDAQ:CLDX )
HAMPTON, N.J., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Celldex ( NASDAQ:CLDX ) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer.
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 - Altimmune ( NASDAQ:ALT )
AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-invasive tests vs. placebo at 24 weeks
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement ...
Altimmune to Participate in Two Upcoming Investor Conferences
GAITHERSBURG, Md., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will ...
Altimmune to Participate in Two Upcoming Investor Conferences - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( NASDAQ:ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will ...
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder - Altimmune ( NASDAQ:ALT )
Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( NASDAQ:ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results ...
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
GAITHERSBURG, Md., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial ...
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025 - Altimmune ( NASDAQ:ALT )
Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
Oral presentation to highlight 24-week efficacy and safety data ...
Important Notice to Long-Term Shareholders of Altimmune, Inc. ( NASDAQ: ALT ) ; Five Below, Inc. ( NASDAQ: FIVE ) ; Flywire Corporation ( NASDAQ: FLYW ) ; and Hertz Global Holdings, Inc. ( NASDAQ: HTZ ) : Grabar Law Office is Investigating Claims on Your Behalf - Five Below ( NASDAQ:FIVE ) , Altimmune ( NASDAQ:ALT )
PHILADELPHIA, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating claims on behalf of shareholders of Altimmune, Inc. ( NASDAQ:ALT ) . The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Altimmune ( NASDAQ:ALT )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune ( ALT ) To Contact Him Directly To Discuss Their Options
Investors who lost money on Altimmune, Inc. ( ALT ) should contact Levi & Korsinsky about pending Class Action - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ( "Altimmune" or the "Company" ) ( NASDAQ:ALT ) of a class action securities lawsuit.
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline - Altimmune ( NASDAQ:ALT )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune ( ALT ) To Contact Him Directly To Discuss Their Options
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Altimmune ( NASDAQ:ALT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
ALT FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $50K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ( NASDAQ:ALT ) between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead plaintiff deadline.
ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm - Altimmune ( NASDAQ:ALT )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune ( ALT ) To Contact Him Directly To Discuss Their Options
ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ( NASDAQ:ALT ) between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead plaintiff deadline.
Portnoy Law Firm Announces Class Action on Behalf of Altimmune, Inc. Investors - Altimmune ( NASDAQ:ALT )
LOS ANGELES, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Altimmune, Inc., ( "Altimmune" or the "Company" ) ( NASDAQ:ALT ) investors of a class action on behalf of investors that bought securities between August 10, 2023, and June 25, 2025, inclusive ( the "Class Period" ) .
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Altimmune ( NASDAQ:ALT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
DEADLINE APPROACHING: Berger Montague Advises Altimmune, Inc. ( NASDAQ: ALT ) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025 - Altimmune ( NASDAQ:ALT )
PHILADELPHIA, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. ( NASDAQ:ALT ) ( "Altimmune" or the "Company" ) following the filing of a securities class action lawsuit filed on behalf of ...
ALTIMMUNE ( ALT ) DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Before the October 6th Deadline in the Altimmune Class Action Lawsuit - Altimmune ( NASDAQ:ALT )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune ( ALT ) To Contact Him Directly To Discuss Their Options
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide - X4 Pharmaceuticals ( NASDAQ:XFOR ) , Altimmune ( NASDAQ:ALT )
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH ...
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ( "Altimmune" or the "Company" ) ( NASDAQ: ALT ) of a class action securities lawsuit.
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT - Altimmune ( NASDAQ:ALT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
ALT DEADLINE: ROSEN, LEADING INVESTOR RIGHTS ATTORNEYS, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ALT between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead plaintiff deadline.
Altimmune to Participate in Two Upcoming Investor Conferences - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ALT, a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be ...
Altimmune to Participate in Two Upcoming Investor Conferences
GAITHERSBURG, Md., Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will ...
Lost Money on Altimmune, Inc. ( ALT ) ? Urged to Join Class Action Before October 6, 2025 - Contact Levi & Korsinsky
Lost Money on Altimmune, Inc. (ALT)? Urged to Join Class Action Before October 6, 2025 - Contact Levi ...
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
New York, New York-- ( Newsfile Corp. - September 20, 2025 ) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ( NASDAQ: ALT ) between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead ...
INVESTOR DEADLINE APPROACHING ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
INVESTOR DEADLINE APPROACHING ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune Lawsuit - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT of a class action securities lawsuit.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ALT between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead plaintiff deadline.
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday - Altimmune ( NASDAQ:ALT ) , ASML Holding ( NASDAQ:ASML )
U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points on Thursday. Shares of Radian Group Inc. RDN rose sharply during Thursday's session after the company announced it entered into a definitive agreement to acquire Inigo for $1.7 billion.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Altimmune ( NASDAQ:ALT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
Shareholders that lost money on Altimmune, Inc. ( ALT ) should contact Levi & Korsinsky about pending Class Action - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT of a class action securities lawsuit.
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ALT between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead plaintiff deadline.
Shareholders that lost money on Altimmune, Inc. ( ALT ) Urged to Join Class Action - Contact The Gross Law Firm to Learn More - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. ALT. Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ALT, a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M.
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
GAITHERSBURG, Md., Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M.
Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm - Altimmune ( NASDAQ:ALT ) , SelectQuote ( NYSE:SLQT )
NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Altimmune, Inc. ALT and SelectQuote, Inc.
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ALT between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead plaintiff deadline.
Class Action Filed Against Altimmune, Inc. - Investors with Losses Encouraged to Contact Johnson Fistel - Altimmune ( NASDAQ:ALT )
SAN DIEGO, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Johnson Fistel, PLLP, announces that a class action lawsuit has been filed on behalf of investors who purchased securities of Altimmune, Inc. ( "Altimmune" ) ALT between August 10, 2023 and June 25, 2025, inclusive ( the ...
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT - Altimmune ( NASDAQ:ALT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm - Altimmune ( NASDAQ:ALT ) , SelectQuote ( NYSE:SLQT )
NEW YORK, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Altimmune, Inc. ALT, SelectQuote, Inc. SLQT and Spectrum Pharmaceuticals, Inc.
